Ptc Therapeutics (PTCT) Accumulated Expenses (2012 - 2026)

Ptc Therapeutics' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $33.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 5.46% year-over-year to $33.8 million in Q1 2026; TTM through Mar 2026 was $33.8 million, a 5.46% increase from a year earlier, with the FY2025 full-year figure at $73.7 million, up 19.75% from the prior year.
• Accumulated Expenses declined to $33.8 million in Q1 2026 per PTCT's latest filing, from $73.7 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $73.7 million in Q4 2025 and bottomed at $29.5 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $46.2 million (2024), against an average of $47.0 million.
• Across the five-year window, Accumulated Expenses jumped 52.63% in 2023 and sank 34.71% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $62.7 million in 2022, then slipped by 0.04% to $62.6 million in 2023, then slipped by 1.7% to $61.6 million in 2024, then gained by 19.75% to $73.7 million in 2025, then tumbled by 54.1% to $33.8 million in 2026.
• Per Business Quant, the three latest PTCT Accumulated Expenses figures stand at $33.8 million (Q1 2026), $73.7 million (Q4 2025), and $49.5 million (Q3 2025).